O	0	3	The
O	4	14	protective
O	15	21	effect
O	22	24	of
B-intervention	25	35	zoledronic
I-intervention	36	40	acid
O	41	43	on
B-condition	44	48	bone
I-condition	49	53	loss
O	54	56	in
O	57	71	postmenopausal
O	72	77	women
O	78	82	with
O	83	88	early
O	89	95	breast
O	96	102	cancer
O	103	110	treated
O	111	115	with
O	116	126	sequential
O	127	136	tamoxifen
O	137	140	and
O	141	150	letrozole
O	150	151	:
O	152	153	a
O	154	165	prospective
O	165	166	,
O	167	177	randomized
O	177	178	,
O	179	184	phase
O	185	187	II
O	188	193	trial
O	193	194	.

O	195	199	This
O	200	205	study
O	206	213	reports
O	214	217	the
O	218	226	efficacy
O	227	230	and
O	231	237	safety
O	238	240	of
O	241	251	zoledronic
O	252	256	acid
O	257	258	(
O	258	261	ZOL
O	261	262	)
O	263	265	in
O	266	276	preventing
O	277	281	bone
O	282	286	loss
O	287	289	in
O	290	304	postmenopausal
O	305	313	patients
O	314	323	receiving
O	324	326	an
O	327	336	aromatase
O	337	346	inhibitor
O	347	348	(
O	348	350	AI
O	350	351	)
O	352	361	following
O	362	371	tamoxifen
O	371	372	.

B-eligibility	373	387	Postmenopausal
I-eligibility	388	396	patients
I-eligibility	397	401	with
I-eligibility	402	407	stage
I-eligibility	408	409	I
I-eligibility	409	410	-
I-eligibility	410	413	III
I-eligibility	414	421	hormone
I-eligibility	422	430	receptor
I-eligibility	430	431	-
I-eligibility	431	439	positive
I-eligibility	440	446	breast
I-eligibility	447	453	cancer
I-eligibility	454	457	who
I-eligibility	458	466	received
I-eligibility	467	476	tamoxifen
I-eligibility	477	480	for
I-eligibility	481	482	2
I-eligibility	482	483	.
I-eligibility	483	484	5
I-eligibility	484	485	-
I-eligibility	485	486	3
I-eligibility	487	492	years
O	493	497	were
O	498	508	randomized
O	509	511	to
O	512	519	receive
B-intervention	520	529	letrozole
O	530	531	(
O	531	532	2
O	532	533	.
O	533	534	5
O	535	537	mg
O	537	538	/
O	538	541	day
O	541	542	)
O	543	547	with
O	548	549	(
O	549	550	n
O	551	552	=
B-intervention-participants	553	555	47
O	555	556	)
O	557	559	or
B-control	560	567	without
O	568	569	(
O	569	570	n
O	571	572	=
B-control-participants	573	575	43
O	575	576	)
O	577	580	ZOL
O	581	582	(
O	582	583	4
O	584	586	mg
O	587	588	i
O	588	589	.
O	589	590	v
O	590	591	.
O	592	597	every
O	598	599	6
O	600	606	months
O	606	607	)
O	608	611	for
O	612	613	2
O	614	619	years
O	619	620	.

O	621	624	The
O	625	632	primary
O	633	641	endpoint
O	642	645	was
B-outcome-Measure	646	653	percent
I-outcome-Measure	654	660	change
I-outcome-Measure	661	665	from
I-outcome-Measure	666	674	baseline
I-outcome-Measure	675	677	in
I-outcome-Measure	678	684	lumbar
I-outcome-Measure	685	690	spine
I-outcome-Measure	691	692	(
I-outcome-Measure	692	694	LS
I-outcome-Measure	694	695	)
I-outcome-Measure	696	700	bone
I-outcome-Measure	701	708	mineral
I-outcome-Measure	709	716	density
I-outcome-Measure	717	718	(
I-outcome-Measure	718	721	BMD
I-outcome-Measure	721	722	)
O	723	725	up
O	726	728	to
O	729	731	60
O	732	738	months
O	738	739	.

B-total-participants	740	746	Ninety
O	747	755	patients
O	756	757	(
B-total-participants	757	759	86
O	760	769	evaluable
O	769	770	)
O	771	775	with
O	776	777	a
O	778	784	median
O	785	788	age
O	789	791	of
B-age	792	794	59
I-age	795	800	years
I-age	801	802	(
I-age	802	804	42
I-age	804	805	.
I-age	805	806	9
I-age	806	807	-
I-age	807	809	83
I-age	809	810	.
I-age	810	811	6
I-age	811	812	)
O	812	813	,
O	814	816	50
O	816	817	/
O	817	819	86
O	820	822	of
O	823	827	whom
O	828	831	had
O	832	842	previously
O	843	847	been
O	848	855	treated
O	856	860	with
O	861	873	chemotherapy
O	873	874	,
O	875	879	were
O	880	888	followed
O	889	892	for
O	893	894	a
O	895	901	median
O	902	906	time
O	907	909	of
O	910	912	41
O	912	913	.
O	913	914	4
O	915	921	months
O	921	922	.

O	923	928	While
O	929	932	the
O	933	940	control
O	941	946	group
O	947	953	showed
O	954	955	a
O	956	967	significant
O	968	976	decrease
O	977	979	in
B-outcome	980	982	LS
I-outcome	983	984	T
I-outcome	984	985	-
I-outcome	985	990	score
O	991	992	(
O	992	993	p
O	994	995	=
O	996	997	0
O	997	998	.
O	998	1002	0005
O	1002	1003	)
O	1003	1004	,
O	1005	1008	the
O	1009	1012	ZOL
O	1013	1018	group
O	1019	1028	presented
O	1029	1031	an
O	1032	1040	increase
O	1041	1045	over
O	1046	1050	time
O	1051	1052	(
O	1052	1053	p
O	1054	1055	=
O	1056	1057	0
O	1057	1058	.
O	1058	1062	0143
O	1062	1063	)
O	1063	1064	.

B-outcome	1065	1071	Change
I-outcome	1072	1076	over
I-outcome	1077	1081	time
I-outcome	1082	1084	in
I-outcome	1085	1087	LS
I-outcome	1088	1089	T
I-outcome	1089	1090	-
I-outcome	1090	1095	score
O	1096	1099	was
O	1100	1113	significantly
O	1114	1123	different
O	1124	1131	between
O	1132	1138	groups
O	1138	1139	,
O	1140	1148	favoring
O	1149	1152	ZOL
O	1153	1154	(
O	1154	1155	p
O	1156	1157	<
O	1158	1159	0
O	1159	1160	.
O	1160	1164	0001
O	1165	1167	at
O	1168	1170	24
O	1171	1174	and
O	1175	1177	48
O	1178	1184	months
O	1184	1185	)
O	1185	1186	.

O	1187	1189	No
B-outcome	1190	1199	fractures
I-outcome	1199	1200	,
I-outcome	1201	1206	renal
I-outcome	1207	1218	dysfunction
I-outcome	1219	1221	or
I-outcome	1222	1235	osteonecrosis
I-outcome	1236	1238	of
I-outcome	1239	1242	the
I-outcome	1243	1246	jaw
O	1247	1251	were
O	1252	1260	reported
O	1260	1261	.

O	1262	1265	The
B-outcome	1266	1274	toxicity
I-outcome	1275	1282	profile
O	1283	1286	was
O	1287	1294	similar
O	1295	1297	to
O	1298	1303	those
O	1304	1314	previously
O	1315	1323	reported
O	1324	1327	for
O	1328	1332	each
O	1333	1337	drug
O	1337	1338	.

O	1339	1342	The
O	1343	1351	addition
O	1352	1354	of
O	1355	1358	ZOL
O	1359	1361	to
O	1362	1371	letrozole
O	1372	1375	was
O	1376	1380	safe
O	1381	1384	and
O	1385	1396	efficacious
O	1397	1399	in
O	1400	1411	maintaining
O	1412	1414	LS
O	1415	1418	BMD
O	1419	1421	in
O	1422	1436	postmenopausal
O	1437	1445	patients
O	1446	1450	with
O	1451	1458	hormone
O	1459	1467	receptor
O	1467	1468	-
O	1468	1476	positive
O	1477	1483	breast
O	1484	1490	cancer
O	1491	1494	and
O	1495	1498	who
O	1499	1503	were
O	1504	1513	receiving
O	1514	1523	letrozole
O	1524	1533	following
O	1534	1535	2
O	1535	1536	.
O	1536	1537	5
O	1537	1538	-
O	1538	1539	3
O	1540	1545	years
O	1546	1548	of
O	1549	1558	tamoxifen
O	1558	1559	.
